Back to Trials
NCT07169825NARecruiting

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

M.D. Anderson Cancer Center

Start Date

3/30/2026

Completion Date

9/1/2028

Summary

To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

Detailed Description

Primary Objectives • To determine the personalized radiation dose to tumors and critical organs of participants with compromised renal and / or bone marrow function. Secondary Objectives * To compare target radiation doses based on varying SPECT scan duration. Plot the variability in target radiation dose versus scan duration. * To compare the image quality and dosimetry results when considering the low, high, and both energy peaks of Lu-177. * To compare target radiation doses based on multiple imaging time points versus a single time point and identify which time point is most suited for this evaluation. * To compare target radiation doses derived from organ versus voxel dosimetry calculation.

Eligibility Criteria

Age Range: No minimum to No maximum

Eligibility Criteria * Participants that are approved for Pluvicto therapy and have been identified to have renal complications or compromised marrow function. Renal complication is defined as GFR: 30-50ml/min, creatinine: ULN-twofold ULN; while compromised marrow function is indicated by total WBC 2.5 x 109 L - LLN, or platelet count 75-100 x 109 L. * Participants who agree to be imaged multiple times as defined in the study protocol. Exclusion Criteria * Pluvicto therapy patients without renal or marrow function complications * Participants who do not wish to be imaged multiple times as per the study protocol. * Women and children since this is treatment for prostate cancer.

Interventions

DRUG

Lu-177

OTHER

SPECT

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lu-177 PSMA

Locations

MD Anderson Cancer Center

Houston, Texas 77030

United States